Percheron Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Operating Revenue	-	-	-	1.96	-
Other Revenue	0.84	1.8	2.97	-	1.78
Revenue	0.84	1.8	2.97	1.96	1.78
Revenue Growth	-53.16%	-39.32%	51.07%	10.51%	207.72%
Cost of Revenue	0.18	0.17	0.06	0.03	0.07
Gross Profit	0.66	1.63	2.91	1.93	1.71
Selling, General & Admin	2.78	4.15	3.84	2.84	2.8
Research & Development	2.09	10.77	10.7	10.16	4.54
Operating Expenses	5.44	16.54	14.82	13.31	7.55
Operating Income	-4.78	-14.91	-11.92	-11.38	-5.83
Interest Expense	-0.02	-0.01	-0	-0.01	-0.01
Interest & Investment Income	-	-	-	-	0.03
Currency Exchange Gain (Loss)	-	-	-	0.01	-0
EBT Excluding Unusual Items	-4.79	-14.92	-11.92	-11.38	-5.81
Pretax Income	-4.79	-14.92	-11.92	-11.38	-5.81
Net Income	-4.79	-14.92	-11.92	-11.38	-5.81
Net Income to Common	-4.79	-14.92	-11.92	-11.38	-5.81
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	1,169	1,024	881	669	634
Shares Outstanding (Diluted)	1,169	1,024	881	669	634
Shares Change	14.12%	16.22%	31.74%	5.45%	17.25%
EPS (Basic)	-0.00	-0.01	-0.01	-0.02	-0.01
EPS (Diluted)	-0.00	-0.01	-0.01	-0.02	-0.01
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Free Cash Flow	-4.97	-15.65	-10.12	-8.18	-7.81
Free Cash Flow Per Share	-0.00	-0.01	-0.01	-0.01	-0.01
Gross Margin	78.74%	90.71%	97.91%	98.32%	96.31%
Operating Margin	-566.19%	-827.68%	-401.45%	-579.21%	-328.10%
Profit Margin	-568.01%	-828.51%	-401.57%	-579.19%	-326.89%
Free Cash Flow Margin	-589.03%	-868.97%	-340.93%	-416.36%	-439.23%
EBITDA	-4.56	-14.84	-11.84	-11.37	-5.83
D&A For EBITDA	0.22	0.07	0.08	0.01	0.01
EBIT	-4.78	-14.91	-11.92	-11.38	-5.83
Revenue as Reported	-	-	-	-	1.81